Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ARCAGY/ GINECO GROUP
With
Hoffmann-La Roche
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
18 years or older; patients with histologically proven diagnosis of ovarian cancer.
Patients with metastatic disease and an overexpression of HER2 (as determined by immunochemistry)
Patients who have progressed while receiving treatment, or within 6 months after completion of treatment. Patients must have received carboplatin and paclitaxel.
Patients who have received at minimum one line of chemotherapy
3 weeks minimum since last treatment with chemotherapy must have elapsed
Patients must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) or an assessable cancer antigen (CA) 125 \> 1.25 x upper limit of normal (ULN)
Patients must have ECOG of 2 or less
Left ventricular ejection fraction (LVEF) of 50% or better
Patients have given their signed and verbal consent
You may not be if
Previous treatment with Herceptin or similar products affected growth factors (eg: Iressa)
Another experimental treatment in the previous 30 days
No overexpression of HER2 receptors
Patients having received high-dose chemotherapy or stem-cell interventions
Other cancers within the last 5 years
Patients with dyspnea at rest or requiring oxygen therapy
Clareo Health | Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer
